ArticleResearch square2026
Longitudinal resting-state EEG-based modeling predicts phenoconversion and delineates heterogeneity in isolated REM sleep behavior disorder.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Isolated REM sleep behavior disorder is a high-risk prodromal syndrome for Lewy body diseases but highly heterogeneous. Neurophysiologic markers resolving this heterogeneity and predicting phenoconversion remain limited. We applied Subtype and Stage Inference (SuStaIn) modeling to longitudinal resting-state EEG from a prospective cohort of 285 participants. SuStaIn identified two subtypes: Subtype 1, a posterior beta-dominant, largely non-progressive phenotype associated with higher educational attainment and absence of phenoconversion, and Subtype 2, a frontal slow-wave-dominant phenotype characterized by progressive delta/theta increases and cognitive decline. Longitudinal validation demonstrated substantial subtype shifting in Subtype 1 and stage advancement predominantly in Subtype 2. In Kaplan-Meier analysis, subtype shifting and accelerated annual stage advancement (ΔStage ≥ 2) identified individuals at exceptionally high phenoconversion risk with survival approaching 0-15% by 7.5 years. These findings extend SuStaIn beyond cross-sectional inference by incorporating longitudinal subtype-shifting and stage-advancement features to stratify prodromal heterogeneity and predict neurodegenerative progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.